Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900263 · ClinicalTrials.gov registry record
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
A clinical trial of Multiple Myeloma and Plasma Cell Myeloma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 375
- Enrollment target
- 20
- Study locations
NCT00900263 is a study of Multiple Myeloma and Plasma Cell Myeloma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 375 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00900263, a study of Multiple Myeloma and Plasma Cell Myeloma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and bone marrow samples from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma.
Conditions Studied
Interventions
- GENETIC microarray analysis
- OTHER biologic sample preservation procedure
- OTHER laboratory biomarker analysis
- GENETIC cytogenetic analysis
Study Locations (20)
Kansas
- Menorah Medical Center - Overland Park
- Saint Luke's Hospital - South - Overland Park
- Tammy Walker Cancer Center at Salina Regional Health Center - Salina
- Shawnee Mission Medical Center - Shawnee Mission
- Cotton-O'Neil Cancer Center - Topeka
Missouri
- Saint Luke's Cancer Institute at Saint Luke's Hospital - Kansas City
- St. Joseph Medical Center - Kansas City
- North Kansas City Hospital - Kansas City
- Parvin Radiation Oncology - Kansas City
- Heartland Hematology Oncology Associates, Incorporated - Kansas City
Arkansas
- Highlands Oncology Group - Springdale - Bentonville
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
- Clemens Regional Medical Center - Mount Clemens
Alabama
- Providence Cancer Center at Providence Hospital - Mobile
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Illinois
- Veterans Affairs Medical Center - Hines - Hines
Louisiana
- Tulane Cancer Center Office of Clinical Research - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2002-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900263
The ClinicalTrials.gov registry entry for NCT00900263 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (31% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which microarray analysis is the first listed.
NCT00900263 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Kansas, Missouri, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00900263 about?
NCT00900263 is a clinical study titled "S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma". RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also h...
What is the current status of trial NCT00900263?
This trial is currently completed. The enrollment target is 375 participants. The study started on 2002-06.
What conditions does trial NCT00900263 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition.
What interventions are being tested in trial NCT00900263?
The interventions under investigation include: microarray analysis (GENETIC), biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), cytogenetic analysis (GENETIC).
Who is sponsoring clinical trial NCT00900263?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00900263 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.